EcoDrugPlus

Fibroblast Growth Factor Receptor 1-A-Like

Ensembl ID : ENSATEG00000004876
Gene Symbol: LOC113158992
3 Cross references
201 Possible Orthologues:

Fibroblast Growth Factor Receptor 1a

Ensembl ID : ENSATEG00000018809
Gene Symbol: FGFR1A
3 Cross references
208 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSATEG00000013574
Gene Symbol: FGFR2
1 Cross references
221 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSATEG00000018092
Gene Symbol: FGFR3
1 Cross references
191 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSATEG00000010898
Gene Symbol: FLT1
3 Cross references
199 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSATEG00000003469
Gene Symbol: FLT4
3 Cross references
197 Possible Orthologues:

Folate Receptor Gamma

Ensembl ID : ENSATEG00000006561
Gene Symbol: FOLR3
3 Cross references
436 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSATEG00000002215
Gene Symbol: FSHR
3 Cross references
201 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSATEG00000008424
Gene Symbol: LOC113170964
2 Cross references
340 Possible Orthologues:

Free Fatty Acid Receptor 3-Like

Ensembl ID : ENSATEG00000005141
Gene Symbol: LOC113154912
2 Cross references
319 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSATEG00000012166
Gene Symbol: FRK
3 Cross references
217 Possible Orthologues:

Galactosidase, Alpha

Ensembl ID : ENSATEG00000000487
Gene Symbol: GLA
1 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).